A review says diabetic wounds stay open when immune cells remain stuck in inflammation; it is not a new patient trial

What the research found

Review (not a new clinical trial). ScienceDaily carried the Higher Education Press account on 9 October 2026. Yi Ru, Yunxi Cai, and colleagues report in MedScience (2025; 19(6):950; doi 10.1007/s11684-025-1190-y). The news date is later than the journal year. The review covers monocytes, macrophages, dendritic cells, neutrophils, mast cells, B cells, T cells, and natural killer cells across the stages of wound healing. It says more than 131 million people have chronic diabetic ulcers, with about $755 billion a year in costs, and with amputation and death among the risks. The authors' reading is that macrophages in diabetic wounds often stay in a pro-inflammatory state instead of shifting toward repair. They also describe poorly controlled neutrophil traps, different mast-cell behavior, weaker debris cleanup by dendritic cells, and fewer or less active regulatory T cells. SLC7A11 is named as one transporter that may be less active in diabetes. The piece discusses experimental ideas, including drugs that push macrophages toward repair, stem-cell vesicles, dressings, and an IL-15 superagonist, and it says timing may matter because each healing stage has a different immune mix. Some of those ideas are described as having early randomized data and some as still laboratory work. The release does not give one new patient sample, sex split, or age band. Educational notes. This is not wound-care advice and not a product claim.

Evidence level: Clinical trial. This is among the stronger kinds of evidence, but one study rarely settles a question.

Read the original at Higher Education Press / MedScience